AAPL   380.18 (-0.31%)
MSFT   212.09 (-0.35%)
FB   240.07 (-1.44%)
GOOGL   1,500.48 (-0.21%)
AMZN   3,087.46 (+0.21%)
NVDA   410.60 (+0.48%)
CGC   15.78 (-3.37%)
BABA   257.08 (-0.23%)
MU   48.95 (-1.53%)
GE   6.63 (-3.35%)
TSLA   1,361.13 (-0.35%)
AMD   54.99 (+2.92%)
T   29.42 (-3.45%)
ACB   11.49 (-5.59%)
GILD   74.60 (-1.34%)
DIS   116.06 (-0.51%)
BAC   22.49 (-2.64%)
NFLX   496.73 (-1.20%)
BA   174.07 (-3.34%)
AAPL   380.18 (-0.31%)
MSFT   212.09 (-0.35%)
FB   240.07 (-1.44%)
GOOGL   1,500.48 (-0.21%)
AMZN   3,087.46 (+0.21%)
NVDA   410.60 (+0.48%)
CGC   15.78 (-3.37%)
BABA   257.08 (-0.23%)
MU   48.95 (-1.53%)
GE   6.63 (-3.35%)
TSLA   1,361.13 (-0.35%)
AMD   54.99 (+2.92%)
T   29.42 (-3.45%)
ACB   11.49 (-5.59%)
GILD   74.60 (-1.34%)
DIS   116.06 (-0.51%)
BAC   22.49 (-2.64%)
NFLX   496.73 (-1.20%)
BA   174.07 (-3.34%)
AAPL   380.18 (-0.31%)
MSFT   212.09 (-0.35%)
FB   240.07 (-1.44%)
GOOGL   1,500.48 (-0.21%)
AMZN   3,087.46 (+0.21%)
NVDA   410.60 (+0.48%)
CGC   15.78 (-3.37%)
BABA   257.08 (-0.23%)
MU   48.95 (-1.53%)
GE   6.63 (-3.35%)
TSLA   1,361.13 (-0.35%)
AMD   54.99 (+2.92%)
T   29.42 (-3.45%)
ACB   11.49 (-5.59%)
GILD   74.60 (-1.34%)
DIS   116.06 (-0.51%)
BAC   22.49 (-2.64%)
NFLX   496.73 (-1.20%)
BA   174.07 (-3.34%)
AAPL   380.18 (-0.31%)
MSFT   212.09 (-0.35%)
FB   240.07 (-1.44%)
GOOGL   1,500.48 (-0.21%)
AMZN   3,087.46 (+0.21%)
NVDA   410.60 (+0.48%)
CGC   15.78 (-3.37%)
BABA   257.08 (-0.23%)
MU   48.95 (-1.53%)
GE   6.63 (-3.35%)
TSLA   1,361.13 (-0.35%)
AMD   54.99 (+2.92%)
T   29.42 (-3.45%)
ACB   11.49 (-5.59%)
GILD   74.60 (-1.34%)
DIS   116.06 (-0.51%)
BAC   22.49 (-2.64%)
NFLX   496.73 (-1.20%)
BA   174.07 (-3.34%)
Log in

LON:NCYTNovacyt Share Price, Forecast & News

GBX 277.50
-0.50 (-0.18 %)
(As of 07/9/2020 11:12 AM ET)
Add
Compare
Today's Range
273
Now: GBX 277.50
287
50-Day Range
215
MA: GBX 271.74
345
52-Week Range
6.03
Now: GBX 277.50
529
Volume249,631 shs
Average VolumeN/A
Market Capitalization£195.99 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Novacyt S.A. develops and sells diagnostic products for cancer and infectious diseases. The company's diagnostic products are used in liquid based cytology, oncology, microbiology, haematology, and serology testing. It offers NovaPrep, a liquid based cytology solution that is utilized in the diagnosis of cervical cancer; and clinical laboratory testing services to clinicians, healthcare providers, and patients. The company also develops, manufactures, and distributes diagnostic products for clinical and food laboratories; and manufactures and markets vitro diagnostic tests, as well as diagnostic reagents, test kits, and blood grouping reagents. It serves hospitals and large corporates. The company was founded in 2006 and is based in Vélizy-Villacoublay, France.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.00 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone33 1 39 46 51 04

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book ValueGBX 116.20 per share

Profitability

Miscellaneous

Employees121
Market Cap£195.99 million
Next Earnings DateN/A
OptionableNot Optionable

Receive NCYT News and Ratings via Email

Sign-up to receive the latest news and ratings for NCYT and its competitors with MarketBeat's FREE daily newsletter.

Novacyt (LON:NCYT) Frequently Asked Questions

How has Novacyt's stock been impacted by COVID-19 (Coronavirus)?

Novacyt's stock was trading at GBX 107.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NCYT shares have increased by 158.1% and is now trading at GBX 277.50. View which stocks have been most impacted by Coronavirus.

Has Novacyt been receiving favorable news coverage?

Media coverage about NCYT stock has trended negative this week, InfoTrie reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Novacyt earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Novacyt.

Who are some of Novacyt's key competitors?

What other stocks do shareholders of Novacyt own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novacyt investors own include Ecolab (ECL), Tiziana Life Sciences (TILS), Alacer Gold (ASR), Alliance Resource Partners (ARLP), Aquestive Therapeutics (AQST), Blue Apron (APRN), CELLECT BIOTECH/S (APOP), Amgen (AMGN), AEGON (AGN) and Adept Technology Group (ADT).

Who are Novacyt's key executives?

Novacyt's management team includes the following people:
  • Mr. Graham Mullis, CEO & Director (Age 56)
  • Mr. Anthony Dyer, CFO, Company Sec. & Director
  • Ms. Mandy Cowling, Corp. & Investor Relations Mang.
  • Ms. Wendy Karban, Group HR Mang.
  • Mr. Phillip Sefton, Managing Director of Lab21 Products Division

What is Novacyt's stock symbol?

Novacyt trades on the London Stock Exchange (LON) under the ticker symbol "NCYT."

How do I buy shares of Novacyt?

Shares of NCYT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Novacyt's stock price today?

One share of NCYT stock can currently be purchased for approximately GBX 277.50.

How big of a company is Novacyt?

Novacyt has a market capitalization of £195.99 million. Novacyt employs 121 workers across the globe.

What is Novacyt's official website?

The official website for Novacyt is www.novacyt.com.

How can I contact Novacyt?

The company can be reached via phone at 33 1 39 46 51 04.

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.